Quick Answer
ANI PHARMACEUTICALS INC reported Long Term Debt of $291.84 million for the year ending 2025.
- ANI PHARMACEUTICALS INC showed a decrease of -5.6% in Long Term Debt from 2024 to 2025.
- This data is from ANI PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $68.57 million | Q2 2018: $67.26 million | Q3 2018: $65.95 million | Q1 2019: $66.50 million | Q2 2019: $65.69 million | Q3 2019: $64.87 million | Q1 2020: $188.09 million | Q2 2020: $177.88 million | Q3 2020: $175.16 million | Q1 2021: $168.99 million | Q2 2021: $189.53 million | Q3 2021: $186.06 million | Q1 2022: $286.31 million | Q2 2022: $286.10 million | Q3 2022: $285.88 million | Q1 2023: $285.46 million | Q2 2023: $285.24 million | Q3 2023: $285.03 million | Q1 2024: $284.61 million | Q2 2024: $284.39 million | Q3 2024: $312.92 million | Q1 2025: $305.29 million | Q2 2025: $301.48 million | Q3 2025: $297.68 million.
- Historical annual values: Fiscal year 2025: $291.84 million | Fiscal year 2024: $309.11 million | Fiscal year 2023: $284.82 million | Fiscal year 2022: $285.67 million | Fiscal year 2021: $286.52 million | Fiscal year 2020: $172.44 million | Fiscal year 2019: $175.81 million | Fiscal year 2018: $67.30 million | Fiscal year 2017: $69.95 million | Fiscal year 2016: $0.00.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: